1. Home
  2. Stocks
  3. Aplltd Share Price

Alembic Pharmaceuticals Share Price

Pharmaceuticals Large Cap

₹1,127.25 +3.4 (0.3%)

05 Nov, 2024 20:57

SIP TrendupStart SIP in APLLTD

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹1,111
  • High
  • ₹1,137
  • 52 Week Low
  • ₹710
  • 52 Week High
  • ₹1,304
  • Open Price₹1,118
  • Previous Close₹1,124
  • Volume55,679

Investment Returns

  • Over 1 Month -9.3%
  • Over 3 Month -9.46%
  • Over 6 Month + 10.05%
  • Over 1 Year + 54.96%
SIP Lightning

Smart Investing Starts Here Start SIP with Alembic Pharmaceuticals for Steady Growth!

Alembic Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 35.2
  • PEG Ratio
  • 1.8
  • Market Cap Cr
  • 22,158
  • P/B Ratio
  • 4.6
  • Average True Range
  • 45.64
  • EPS
  • 33.9
  • Dividend Yield
  • 1
  • MACD Signal
  • -18.04
  • RSI
  • 48.89
  • MFI
  • 22.74

Alembic Pharmaceuticals Financial

IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations1,475.561,474.551,588.391,478.841,332.27
Total Income From Operations1,475.561,474.551,588.391,478.841,332.27
P/L Before Interest, Excpt. Items & Tax225.89226.29271.36149.23111.82
P/L Before Exceptional Items & Tax213.20216.16256.70133.8497.53
P/L After Tax from Ordinary Activities176.19201.87233.24133.8497.53
Net Profit/Loss For the Period176.19201.87233.24133.8497.53
IndicatorMar 24Mar 23
Revenue From Operations [Gross]5,757.555,003.13
Revenue From Operations [Net]5,757.555,003.13
Total Operating Revenues5,874.065,149.00
Total Revenue5,905.385,152.54
Total Expenses5,201.154,806.60
Profit/Loss Before Tax704.23345.94
Profit/Loss For The Period666.48346.73
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity772.77730.25
Net Cash Used In Investing Activity-329.02-460.98
Net Cash Used in Finance Activity-445.29-261.16
Net Inc/Dec In Cash And Equivalent-1.548.11
Cash And Equivalent End Of Year20.1321.67
IndicatorMar 24Mar 23
Total Share Capital39.3139.31
Total Non-Current Liabilities162.42164.83
Total Current Liabilities1,327.211,551.30
Total Capital And Liabilities6,398.546,130.42
Total Non-Current Assets3,409.993,350.20
Total Current Assets2,988.552,780.22
Total Assets6,398.546,130.42
Indicator20242023
EBIT Margin (%)12.917.67
Return On Capital Employed (%)14.968.62
Return On Equity (%)13.577.85
Long Term Debt To Equity (%)0.000.00
Book Value/Share (INR)249.75224.59
IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations1,561.731,516.981,630.571,594.931,486.15
Total Income From Operations1,561.731,516.981,630.571,594.931,486.15
P/L Before Interest, Excpt. Items & Tax169.89194.18199.80150.84144.18
P/L Before Exceptional Items & Tax156.71183.24184.63135.15129.79
P/L After Tax from Ordinary Activities134.22178.60180.50137.06120.63
Net Profit/Loss For the Period134.22178.60180.50137.06120.63
IndicatorMar 24Mar 23
Revenue From Operations [Gross]6,112.115,499.77
Revenue From Operations [Net]6,112.115,499.77
Total Operating Revenues6,228.625,652.62
Total Revenue6,256.935,655.36
Total Expenses5,624.135,269.84
Profit/Loss Before Tax632.80385.52
Profit/Loss For The Period616.80372.91
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity803.20723.95
Net Cash Used In Investing Activity-320.61-447.59
Net Cash Used in Finance Activity-437.86-261.96
Net Inc/Dec In Cash And Equivalent44.7314.40
Cash And Equivalent End Of Year120.2175.48
IndicatorMar 24Mar 23
Total Share Capital39.3139.31
Total Non-Current Liabilities172.39175.43
Total Current Liabilities1,454.991,636.93
Total Capital And Liabilities6,445.586,182.83
Total Non-Current Assets3,367.023,272.81
Total Current Assets3,078.562,910.02
Total Assets6,445.586,182.83
Indicator20242023
EBIT Margin (%)11.067.70
Return On Capital Employed (%)13.809.58
Return On Equity (%)12.787.82
Long Term Debt To Equity (%)0.000.00
Book Value/Share (INR)245.14222.36

Alembic Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,127.25
+ 3.4 (0.3%)
pointer
  • stock-down_img
  • Bullish Moving Average 11
  • stock-up_img
  • Bearish Moving Average 5
  • 20 Day
  • ₹1,126.30
  • 50 Day
  • ₹1,133.75
  • 100 Day
  • ₹1,101.67
  • 200 Day
  • ₹1,027.88

Resistance and Support

1125.25 Pivot Speed
  • R3 1,165.55
  • R2 1,151.45
  • R1 1,139.35
  • S1 1,113.15
  • S2 1,099.05
  • S3 1,086.95

Is Alembic Pharmaceuticals Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Alembic Pharmaceuticals Limited, manufactures and markets India Formulations, International Generics, and Active Pharmaceutical Ingredients (APIs). With a strong R&D focus, Alembic derives over $600 million in revenue, with significant contributions from India and the US markets. Alembic Pharmaceuticals has an operating revenue of Rs. 6,304.21 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 10% is healthy, ROE of 12% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 9% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -12% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 42 which is a POOR score indicating inconsistency in earnings, a RS Rating of 54 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 32 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Alembic Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-07 Quarterly Results
2024-08-08 Quarterly Results
2024-05-09 Audited Results & Final Dividend
2024-02-05 Quarterly Results
2023-11-07 Quarterly Results
Date Purpose Remarks
2024-07-15 FINAL Rs.11.00 per share(550%)Final Dividend
2023-07-28 FINAL Rs.8.00 per share(400%)Final Dividend
2022-08-18 INTERIM Rs.10.00 per share(500%)Dividend (Changed Final Dividend as Interim Divided)

Alembic Pharmaceuticals F&O

Alembic Pharmaceuticals Shareholding Pattern

69.61%
8.9%
6.71%
3.94%
0.03%
7.35%
3.46%
  • NSE Symbol
  • APLLTD
  • BSE Symbol
  • 533573
  • Managing Director
  • Mr. Pranav Amin
  • ISIN
  • INE901L01018

Alembic Pharmaceuticals FAQs

Alembic Pharmaceuticals share price is ₹1,127 As on 05 November, 2024 | 20:43

The Market Cap of Alembic Pharmaceuticals is ₹22157.6 Cr As on 05 November, 2024 | 20:43

The P/E ratio of Alembic Pharmaceuticals is 35.2 As on 05 November, 2024 | 20:43

The PB ratio of Alembic Pharmaceuticals is 4.6 As on 05 November, 2024 | 20:43

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.